**AI生物标志物分析公司Nucleai完成1400万美元B+轮融资，引领医疗影像智能化新趋势**
近日，专注于AI空间生物标志物分析的初创公司Nucleai宣布成功获得1400万美元的B+轮融资，本轮融资由知名投资机构M Ventures领投，Section 32、Sanofi Ventures、Debiopharm、复星锐正资本、Vertex Ventures Israel以及Grove Ventures等现有投资者跟投。这一轮融资的完成，不仅彰显了市场对Nucleai技术实力和未来前景的高度认可，也为公司进一步推进人工智能在医疗领域的应用提供了强大的资金支持。
Nucleai利用先进的AI技术和机器学习算法，深度挖掘细胞和组织层面的病理图像及空间数据，以预测疾病治疗的可能结果。这一创新技术有望革新医疗诊断和治疗方案的制定过程，提高临床决策的准确性和效率。通过将人工智能与生物医学研究相结合，Nucleai正逐步打开医疗影像分析的新篇章，为精准医疗领域带来突破性进展。
随着这笔资金的注入，Nucleai计划加速其产品研发，加强技术团队建设，并扩大市场影响力，以满足全球范围内对精准医疗解决方案日益增长的需求。Nucleai的创始人及首席执行官表示，他们将致力于推动AI在病理学和生物标志物分析中的应用，以帮助医生和研究人员更准确地理解疾病，为患者提供更个性化的治疗方案。
此次融资的成功，预示着Nucleai在AI驱动的医疗影像分析领域将有更大的作为，同时也预示着医疗科技行业的未来趋势——将人工智能技术与生物医学深度结合，以实现医疗诊断和治疗的智能化。
英语如下：
**News Title:** “AI Biomarker Analysis Company Nucleai Raises $14M in B+ Round, Pioneering the Era of Intelligent Pathology Image Analysis”
**Keywords:** AI bioanalysis, Nucleai funding, pathology image recognition
**News Content:**
Nucleai, a startup specializing in AI-based spatial biomarker analysis, recently announced the successful completion of a $14 million B+ funding round, led by prominent investor M Ventures. Section 32, Sanofi Ventures, Debiopharm, Fosun RZ Capital, Vertex Ventures Israel, and Grove Ventures, among existing investors, also participated in the round. The financing underscores the market’s confidence in Nucleai’s technological prowess and future potential, providing a strong financial foundation for the company to advance AI applications in healthcare.
Nucleai harnesses cutting-edge AI and machine learning algorithms to delve into cellular and tissue-level pathology images and spatial data, predicting potential disease treatment outcomes. This innovative technology has the potential to revolutionize diagnostic and treatment planning processes, enhancing the accuracy and efficiency of clinical decision-making. By integrating AI with biomedical research, Nucleai is paving the way for a new era in medical imaging analysis, making breakthroughs in precision medicine.
With the injection of these funds, Nucleai aims to accelerate product development, strengthen its technical team, and expand its market presence to cater to the growing global demand for precision healthcare solutions. The company’s founder and CEO expressed their commitment to advancing AI applications in pathology and biomarker analysis, enabling doctors and researchers to better understand diseases and offer more personalized treatment plans.
This successful funding round signals Nucleai’s substantial role in the AI-driven medical imaging analysis sector and foreshadows the future direction of the healthcare technology industry—integrating artificial intelligence deeply with biomedical sciences for intelligent diagnostics and therapy.
【来源】https://www.calcalistech.com/ctechnews/article/r11brac1a
Views: 1